Liposcience, Inc.

Steven P Matyus

James D Otvos

Elias J Jeyarajah

David R Morgan

Stephen Markham

Bruce D Silberman

Donald R Deuel

Stanley Leon Hazen

Dennis W Bennett

Justyna E Wolak-Dinsmore

Thomas M O'Connell

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide ('TMAO'). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 &#x3bc;M or urine with a normal biologic range of between about 0-1000 &#x3bc;M.

NMR quantification of TMAO

The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.

NMR analyzers for clinical evaluation of biosamples

Methods, computer program products and apparatus automate clinical NMR in vitro diagnostic analyzers. The clinical analyzer can automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites; and at least one remote control system in communication with one or a plurality of clinical NMR analyzers, the at least one remote system configured to monitor selected local operating parameters associated with a respective clinical NMR analyzer.

NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples

Growing community of inventors

Durham, NC, United States of America

Steven P Matyus